PE20161376A1 - Anticuerpos de hemaglutinina contra el virus de la influenza b y metodos de uso - Google Patents

Anticuerpos de hemaglutinina contra el virus de la influenza b y metodos de uso

Info

Publication number
PE20161376A1
PE20161376A1 PE2016001760A PE2016001760A PE20161376A1 PE 20161376 A1 PE20161376 A1 PE 20161376A1 PE 2016001760 A PE2016001760 A PE 2016001760A PE 2016001760 A PE2016001760 A PE 2016001760A PE 20161376 A1 PE20161376 A1 PE 20161376A1
Authority
PE
Peru
Prior art keywords
hvr
seq
influenza
virus
hemaglutinin
Prior art date
Application number
PE2016001760A
Other languages
English (en)
Inventor
Mercedesz Balazs
Ning Chai
Nancy Chiang
Henry Chiu
Min Xu
Gerald R Nakamura
Hyunjoo Park
Lee Swem
Zhonghua Lin
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PE20161376A1 publication Critical patent/PE20161376A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

La presente invencion ser refiere a un anticuerpo monoclonal antihemaglutinina aislado que se une especificamente a la hemaglutinina del virus de la influenza B, esta comprendida por: a) tres regiones hipervariables de cadena pesada: HVR-H1 de SEQ ID NO: 63, HVR-H2 de SEQ ID NOs: 67, 68, 69, 70, 71, 72, 73, 74 y HVR-H3 de SEQ ID NO: 77 y b) tres regiones hipervariables de cadena ligera: HVR-L1 de SEQ ID NO: 56, HVR-L2 de SEQ ID NO: 58 y HVR-L3 de SEQ ID NO: 60. Tambien se refiere a un metodo de tratamiento, inhibicion o prevencion, una composicion farmaceutica y un metodo de produccion. Dicho anticuerpo neutraliza el virus de la influenza B, siendo util en el tratamiento de esta infeccion
PE2016001760A 2014-03-27 2015-03-26 Anticuerpos de hemaglutinina contra el virus de la influenza b y metodos de uso PE20161376A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461971123P 2014-03-27 2014-03-27

Publications (1)

Publication Number Publication Date
PE20161376A1 true PE20161376A1 (es) 2016-12-26

Family

ID=52829396

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016001760A PE20161376A1 (es) 2014-03-27 2015-03-26 Anticuerpos de hemaglutinina contra el virus de la influenza b y metodos de uso

Country Status (20)

Country Link
US (2) US9745365B2 (es)
EP (1) EP3122771A1 (es)
JP (1) JP2017512471A (es)
KR (1) KR20160135830A (es)
CN (1) CN106132987A (es)
AR (1) AR099855A1 (es)
AU (1) AU2015235983A1 (es)
BR (1) BR112016022113A2 (es)
CA (1) CA2942820A1 (es)
CL (2) CL2016002413A1 (es)
CR (1) CR20160502A (es)
EA (1) EA201691945A1 (es)
IL (1) IL247870A0 (es)
MA (1) MA39803A (es)
MX (1) MX2016012530A (es)
PE (1) PE20161376A1 (es)
PH (1) PH12016501873A1 (es)
SG (1) SG11201607945UA (es)
TW (1) TW201620932A (es)
WO (1) WO2015148806A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017264754A1 (en) 2016-05-10 2018-12-13 Genentech, Inc. Methods of decreasing trisulfide bonds during recombinant production of polypeptides
BR112020012591A2 (pt) 2017-12-22 2020-11-24 Genentech, Inc. células hospedeiras de integração direcionada (ti), células hospedeiras ti, métodos para preparar uma célula hospedeira ti, métodos para expressar um polipeptídeo de interesse e vetores
SG11202006379UA (en) 2018-01-26 2020-07-29 Regeneron Pharma Human antibodies to influenza hemagglutinin
EP3775184A1 (en) 2018-03-29 2021-02-17 F. Hoffmann-La Roche AG Modulating lactogenic activity in mammalian cells
SG11202106523SA (en) 2018-12-21 2021-07-29 Genentech Inc Targeted integration of nucleic acids
RU2714246C1 (ru) * 2018-12-28 2020-02-13 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт гриппа имени А.А. Смородинцева" Министерства здравоохранения Российской Федерации Моноклональные антитела, специфичные к различным штаммам вируса гриппа в
EP4051707A1 (en) * 2019-10-28 2022-09-07 Regeneron Pharmaceuticals, Inc. Anti-hemagglutinin antibodies and methods of use thereof
CN115348874A (zh) * 2020-01-24 2022-11-15 里珍纳龙药品有限公司 蛋白质-抗病毒化合物偶联物
EP4127153A2 (en) 2020-03-26 2023-02-08 Genentech, Inc. Modified mammalian cells having reduced host cell proteins
KR20230027043A (ko) 2020-06-24 2023-02-27 제넨테크, 인크. 핵산의 표적화 통합
WO2021262783A1 (en) 2020-06-24 2021-12-30 Genentech, Inc. Apoptosis resistant cell lines
CN116648507A (zh) 2020-08-28 2023-08-25 基因泰克公司 宿主细胞蛋白的CRISPR/Cas9多重敲除
CN114316032B (zh) * 2020-09-27 2022-12-27 东莞市朋志生物科技有限公司 抗乙型流感病毒的抗体、检测乙型流感病毒的试剂和试剂盒
CA3215965A1 (en) 2021-04-19 2022-10-27 Amy Shen Modified mammalian cells
WO2022246259A1 (en) 2021-05-21 2022-11-24 Genentech, Inc. Modified cells for the production of a recombinant product of interest

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2921928B1 (fr) 2007-10-08 2011-03-04 Sanofi Pasteur Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal
BE1018561A3 (fr) 2008-12-24 2011-03-01 Galactic Sa Procede de purification de l'acide lactique par cristallisation.
EP2380976A4 (en) 2008-12-25 2012-11-07 Univ Osaka HUMAN ANTIBODY AGAINST HUMAN FLUX VIRUS
CN103906763B (zh) * 2011-07-14 2016-10-12 克鲁塞尔荷兰公司 能够中和系统发育群1和系统发育群2的a型流感病毒以及b型流感病毒的人结合分子
WO2013114885A1 (en) * 2012-01-31 2013-08-08 Osaka University Human monoclonal antibodies broadly protective against influenza b virus and methods of using the same
JP6328061B2 (ja) * 2012-03-08 2018-05-23 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Ｂ型インフルエンザウイルスに結合して中和することができるヒト結合分子およびその使用

Also Published As

Publication number Publication date
PH12016501873A1 (en) 2017-01-09
US20170320937A1 (en) 2017-11-09
AU2015235983A1 (en) 2016-10-06
SG11201607945UA (en) 2016-10-28
US9745365B2 (en) 2017-08-29
TW201620932A (zh) 2016-06-16
CL2016002413A1 (es) 2017-06-23
JP2017512471A (ja) 2017-05-25
MA39803A (fr) 2017-02-01
CL2018002874A1 (es) 2018-12-14
CR20160502A (es) 2017-02-03
CN106132987A (zh) 2016-11-16
IL247870A0 (en) 2016-11-30
US20150274812A1 (en) 2015-10-01
BR112016022113A2 (pt) 2017-10-31
EP3122771A1 (en) 2017-02-01
CA2942820A1 (en) 2015-10-01
EA201691945A1 (ru) 2017-02-28
KR20160135830A (ko) 2016-11-28
WO2015148806A1 (en) 2015-10-01
AR099855A1 (es) 2016-08-24
MX2016012530A (es) 2017-01-05

Similar Documents

Publication Publication Date Title
PE20161376A1 (es) Anticuerpos de hemaglutinina contra el virus de la influenza b y metodos de uso
PE20170935A1 (es) Anticuerpos anti-her2 e inmunoconjugados
ES2685424T3 (es) Anticuerpos anti-Jagged1 y procedimientos de uso
PE20181009A1 (es) ANTICUERPOS ANTI-HtrA1 Y METODOS DE USO DE LOS MISMOS
AR096687A1 (es) Anticuerpos anti-fcrh5
PE20161571A1 (es) Anticuerpos anti-ox40 y metodos de uso
PE20150025A1 (es) Anticuerpos e inmunoconjugados contra ly6e y metodos de uso
PE20141562A1 (es) Anticuerpos anti-htra1 y metodos de uso
PE20150945A1 (es) Anticuerpos de antihemaglutinina y metodos de uso
PE20160712A1 (es) Anticuerpos e inmunoconjugados anti-cd33
PE20150211A1 (es) Anticuerpos e inmunoconjugados anti-cd79b
PE20120877A1 (es) ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS
PE20201186A1 (es) Anticuerpos antitau y metodos de uso
PE20170953A1 (es) ANTICUERPOS ANTI-CD79b Y METODOS DE USO
PE20181336A1 (es) Anticuerpos que se unen a interleucina 8 (il-8) y sus usos
PE20170670A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
PE20120878A1 (es) ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS
AR091701A1 (es) Anticuerpos anti-cd22 e inmunoconjugados
BR112018006579A2 (pt) anticorpos anti-humanos cd19 humanizados e métodos de uso
PE20141722A1 (es) Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
PE20181270A1 (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
PE20240365A1 (es) Anticuerpos anti-c5 y metodos de uso
JP2016503413A5 (es)
AR102594A1 (es) ANTICUERPOS ANTI-IL-1b Y MÉTODOS DE USO
PE20120553A1 (es) Anticuerpos anti-fgfr3